Shorter antiviral protection after stem cell transplant
Part of Infections clinical trials.
This study tests whether a blood test can help doctors decide how long to continue letermovir (a medicine that prevents a common viral infection called CMV) after a stem cell transplant. The goal is to see if a shorter course is safe and effective for some patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You had a stem cell transplant from a half-matched donor (haploidentical) and you have had CMV in the past (CMV IgG positive), or you received a transplant from a donor who had CMV and you have been taking letermovir to prevent CMV since the transplant.
- Your CMV blood test is negative (below 400 copies/mL) within 5 days before joining the study.
- You do not have active CMV infection or disease before joining.
- You have not taken certain antiviral medicines (like ganciclovir, valganciclovir, foscarnet, or high-dose acyclovir) within the last week, or other CMV treatments within the last month.
- You are not on a ventilator or have unstable blood pressure, and you are willing to follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two medications, letermovir and valganciclovir, to see which works better at preventing CMV infection in people who have received a kidney transplant and have previously been exposed to the virus. Taking part may help reduce the risk of a serious infection after transplant.
This trial tests whether taking letermovir for a longer time can prevent CMV (a common virus) from reactivating in adults with certain risk factors after a donor stem cell transplant. If you're preparing for your first transplant and have a high-risk donor or conditioning, this study may be an option.
This trial tests whether doctors can safely stop a CMV prevention medication (letermovir) earlier by using blood tests to check your immune system's strength. CMV is a virus that can become dangerous after stem cell transplant, and this study aims to prevent it while minimizing unnecessary medicine.
This trial tests whether the drug letermovir can prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. It is for adults who are CMV-positive and have not yet had a CMV infection.
This trial uses a blood test to measure your immune system's ability to fight CMV, a common virus after transplant. The results will help your doctors decide if you can safely stop taking the antiviral medication letermovir earlier to avoid unnecessary side effects.
This trial tests whether the medicine letermovir can prevent a common virus (CMV) from coming back after an allogeneic stem cell transplant in children. It may help lower the risk of CMV infection during the vulnerable period right after transplant.
Hear when a new CMV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.